Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Quick Ratio : 0.52 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Clarus Therapeutics Holdings's quick ratio for the quarter that ended in Jun. 2022 was 0.52.

Clarus Therapeutics Holdings has a quick ratio of 0.52. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Clarus Therapeutics Holdings's Quick Ratio or its related term are showing as below:

CRXTQ's Quick Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.33
* Ranked among companies with meaningful Quick Ratio only.

Clarus Therapeutics Holdings Quick Ratio Historical Data

The historical data trend for Clarus Therapeutics Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Quick Ratio Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Quick Ratio

0.23

0.57

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Quick Ratio	Get a 7-Day Free Trial			-	0.51	0.57	0.33	0.52

Competitive Comparison of Clarus Therapeutics Holdings's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Quick Ratio falls into.

Clarus Therapeutics Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Clarus Therapeutics Holdings's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(51.643	-	14.214)	/	66.06
	=	0.57

Clarus Therapeutics Holdings's Quick Ratio for the quarter that ended in Jun. 2022 is calculated as

Quick Ratio (Q: Jun. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(48.88	-	16.805)	/	61.806
	=	0.52

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Clarus Therapeutics Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402